98%
921
2 minutes
20
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/S2213-2600(24)00116-4 | DOI Listing |
Cell Rep
February 2020
Metastasis Research Laboratory, GIGA-Cancer, University of Liège, Liège, Belgium. Electronic address:
The use of cetuximab anti-epidermal growth factor receptor (anti-EGFR) antibodies has opened the era of targeted and personalized therapy in colorectal cancer (CRC). Poor response rates have been unequivocally shown in mutant KRAS and are even observed in a majority of wild-type KRAS tumors. Therefore, patient selection based on mutational profiling remains problematic.
View Article and Find Full Text PDF